Core Viewpoint - Inspira Technologies has received a notice from Nasdaq regarding non-compliance with the minimum market value requirement for publicly held shares, which is set at $35 million, and has until August 18, 2026, to regain compliance [1] Group 1: Compliance and Regulatory Information - The company is currently not in compliance with Nasdaq Listing Rule 5550(b)(2), which mandates a minimum market value of publicly held shares of $35 million [1] - The company has a 180-day period until August 18, 2026, to regain compliance by maintaining a market value of $35 million or more for at least 10 consecutive business days [1] - If compliance is not achieved by the deadline, Nasdaq may initiate delisting procedures, which the company can appeal [1] Group 2: Company Overview - Inspira Technologies is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions [3] - The company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S., with plans for a next-generation system, INSPIRA ART500 [3] - The company is also developing HYLA™, a proprietary blood sensor platform for continuous, non-invasive monitoring, and is positioned as an attractive player in the life-support and MedTech sectors [3]